Skip to main content
. 2015 Jul 22;26(4):123–133. doi: 10.1089/hgtb.2014.135

Figure 1.

Figure 1.

In vivo intramuscular transduction efficacy of rAAV2 serotypes 1, 2, 5, 6, 8, and 9. (a) Representative images from days 7, 14, 21, and 28 of BALB/cJ mice injected intramuscularly with rAAV2/1-CMV-FLuc, rAAV2/2-CMV-FLuc, rAAV2/5-CMV-FLuc, rAAV2/6-CMV-FLuc, rAAV2/8-CMV-FLuc, rAAV2/9-CMV-FLuc, or negative controls. Right: Overexposed images from day 14. (b) Bioluminescence from injected murine hind limb muscle was recorded on days 3, 7, 14, 21, and 28, and the results are based on the bioluminescence light signal intensity computed from a standardized region of interest (depicted as the average radiance + SD) (each group, n = 2). LV, lentiviral vector; rAAV, recombinant adeno-associated virus vector. p/sec/cm2/sr, photons per second per centimeter squared per steradian.